Nuvectis Pharma, Inc. (NVCT)
NASDAQ: NVCT · Real-Time Price · USD
6.56
+0.03 (0.46%)
Aug 29, 2025, 4:00 PM - Market closed

Nuvectis Pharma Statistics

Total Valuation

Nuvectis Pharma has a market cap or net worth of $167.00 million. The enterprise value is $140.20 million.

Market Cap167.00M
Enterprise Value 140.20M

Important Dates

The last earnings date was Tuesday, August 5, 2025, before market open.

Earnings Date Aug 5, 2025
Ex-Dividend Date n/a

Share Statistics

Nuvectis Pharma has 25.46 million shares outstanding. The number of shares has increased by 16.00% in one year.

Current Share Class 25.46M
Shares Outstanding 25.46M
Shares Change (YoY) +16.00%
Shares Change (QoQ) +7.17%
Owned by Insiders (%) 42.90%
Owned by Institutions (%) 14.00%
Float 14.54M

Valuation Ratios

PE Ratio n/a
Forward PE n/a
PS Ratio n/a
Forward PS n/a
PB Ratio 9.28
P/TBV Ratio 9.90
P/FCF Ratio n/a
P/OCF Ratio n/a
PEG Ratio n/a
Financial Ratio History

Enterprise Valuation

EV / Earnings n/a
EV / Sales n/a
EV / EBITDA n/a
EV / EBIT n/a
EV / FCF n/a

Financial Position

The company has a current ratio of 2.66

Current Ratio 2.66
Quick Ratio 2.64
Debt / Equity n/a
Debt / EBITDA n/a
Debt / FCF n/a
Interest Coverage n/a

Financial Efficiency

Return on equity (ROE) is -150.12% and return on invested capital (ROIC) is -97.67%.

Return on Equity (ROE) -150.12%
Return on Assets (ROA) -63.38%
Return on Invested Capital (ROIC) -97.67%
Return on Capital Employed (ROCE) -136.15%
Revenue Per Employee n/a
Profits Per Employee -$1.70M
Employee Count13
Asset Turnover n/a
Inventory Turnover n/a

Taxes

Income Tax n/a
Effective Tax Rate n/a

Stock Price Statistics

The stock price has decreased by -6.55% in the last 52 weeks. The beta is -0.27, so Nuvectis Pharma's price volatility has been lower than the market average.

Beta (5Y) -0.27
52-Week Price Change -6.55%
50-Day Moving Average 7.27
200-Day Moving Average 7.47
Relative Strength Index (RSI) 45.87
Average Volume (20 Days) 108,124

Short Selling Information

The latest short interest is 1.02 million, so 3.99% of the outstanding shares have been sold short.

Short Interest 1.02M
Short Previous Month 1.06M
Short % of Shares Out 3.99%
Short % of Float 6.99%
Short Ratio (days to cover) 4.85

Income Statement

Revenue n/a
Gross Profit n/a
Operating Income -22.97M
Pretax Income -21.10M
Net Income -22.07M
EBITDA n/a
EBIT -22.97M
Earnings Per Share (EPS) -$1.16
Full Income Statement

Balance Sheet

The company has $26.79 million in cash and n/a in debt, giving a net cash position of $26.79 million or $1.05 per share.

Cash & Cash Equivalents 26.79M
Total Debt n/a
Net Cash 26.79M
Net Cash Per Share $1.05
Equity (Book Value) 16.87M
Book Value Per Share 0.71
Working Capital 16.87M
Full Balance Sheet

Cash Flow

Operating Cash Flow -12.41M
Capital Expenditures n/a
Free Cash Flow n/a
FCF Per Share n/a
Full Cash Flow Statement

Margins

Gross Margin n/a
Operating Margin n/a
Pretax Margin n/a
Profit Margin n/a
EBITDA Margin n/a
EBIT Margin n/a
FCF Margin n/a

Dividends & Yields

Nuvectis Pharma does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Years of Dividend Growth n/a
Payout Ratio n/a
Buyback Yield -16.00%
Shareholder Yield -16.00%
Earnings Yield -13.21%
FCF Yield n/a

Analyst Forecast

The average price target for Nuvectis Pharma is $15.33, which is 133.69% higher than the current price. The consensus rating is "Strong Buy".

Price Target $15.33
Price Target Difference 133.69%
Analyst Consensus Strong Buy
Analyst Count 3
Revenue Growth Forecast (5Y) n/a
EPS Growth Forecast (5Y) n/a
Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value n/a
Lynch Upside n/a
Graham Number n/a
Graham Upside n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date n/a
Split Type n/a
Split Ratio n/a

Scores

Altman Z-Score n/a
Piotroski F-Score 1